Basic Information
| LncRNA/CircRNA Name | RP11-381N20.2 |
| Synonyms | NA |
| Region | GRCh38_4:123490268-123522106 |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Paclitaxel | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cervical cancer |
| ICD-0-3 | C53 |
| Methods | qPCR, Western blot |
| Sample | cervical cancer tissues, cell lines (SiHa) |
| Expression Pattern | down-regulated |
| Function Description | qRT-PCR results showed that the expression of RP11-381N20.2 in cervical cancer was decreased, and the total survival time of patients was positively correlated with the expression of RP11-381N20.2. RP11-381N20.2 was associated with TNM (tumor node metastasis) staging and tumor size. Biological functions of SiHa cells showed that the expression of RP11-381N20.2 was negatively correlated with the treatment time and dose of paclitaxel. Colony formation assay showed that paclitaxel could inhibit the proliferation of cervical cancer cells in a dose-dependent manner. Flow cytometry showed that paclitaxel induced apoptosis of cervical cancer cells, which was more promoted after combination with RP11-381N20.2. |
| Pubmed ID | 29863245 |
| Year | 2018 |
| Title | Paclitaxel Inhibits the Progression of Cervical Cancer by Inhibiting Autophagy via lncRNARP11-381N20.2 |
External Links
| Links for RP11-381N20.2 | GenBank HGNC NONCODE |
| Links for cervical cancer | OMIM COSMIC |